1 – 179 of 179
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
2024) In The Lancet Haematology(
- Contribution to journal › Article
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
2024) In Haemophilia(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Real-world prophylactic usage of recombinant factor IX Fc in Sweden : A report from the Swedish National Registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
Koagulationsfaktor XIII – inte bara ett kongenitalt blödningsproblem
(
- Contribution to journal › Scientific review
-
Mark
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
(
- Contribution to journal › Article
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
(
- Contribution to journal › Scientific review
-
Mark
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
(
- Contribution to journal › Article
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
(
- Contribution to journal › Article
-
Mark
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B : post hoc analysis of phase III trials using patient-reported outcomes
(
- Contribution to journal › Article
-
Mark
High use of pain, depression, and anxiety drugs in hemophilia : more than 3000 people with hemophilia in an 11-year Nordic registry study
(
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
- 2022
-
Mark
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B : Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
(
- Contribution to journal › Article
-
Mark
New Inhibitors in the Ageing Population : A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia
(
- Contribution to journal › Article
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
-
Mark
International consensus recommendations on the management of people with haemophilia B
(
- Contribution to journal › Scientific review
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
-
Mark
Autologous cell therapy - A new concept to eradicate inhibitors in haemophilia
(
- Contribution to journal › Letter
-
Mark
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
(
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children : A critical review from the physician's perspective
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
(
- Contribution to journal › Article
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Identification of F8 rearrangements in carrier and non-carrier mothers of haemophilia A patients
(
- Contribution to journal › Letter
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
-
Mark
Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors : A systematic literature review
(
- Contribution to journal › Scientific review
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
(
- Contribution to journal › Article
-
Mark
Efficacy of rfixfc versus rix-fp for the treatment of patients with hemophilia b : Matching-adjusted indirect comparison of b-long and prolong-9fp trials
(
- Contribution to journal › Article
-
Mark
Droplet digital PCR and mile-post analysis for the detection of F8 int1h inversions
(
- Contribution to journal › Article
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
- 2020
-
Mark
Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR
(
- Contribution to journal › Article
-
Mark
Detection of F8 int22h inversions using digital droplet PCR and mile-post assays
(
- Contribution to journal › Article
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
(
- Contribution to journal › Article
- 2019
-
Mark
Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia : A comparison between intermediate- and high-dose prophylaxis
(
- Contribution to journal › Article
-
Mark
Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study
(
- Contribution to journal › Article
-
Mark
Joint comorbidities among Swedish carriers of haemophilia : A register-based cohort study over 22 years
(
- Contribution to journal › Article
-
Mark
Targeted re-sequencing of F8, F9 and VWF : Characterization of Ion Torrent data and clinical implications for mutation screening
(
- Contribution to journal › Article
- 2018
-
Mark
The role of the laboratory in diagnosis and management of inhibitory antibodies in haemophilia
(
- Contribution to journal › Article
- 2017
-
Mark
The importance of genetic factors for the development of arthropathy : A longitudinal study of children and adolescents with haemophilia A
(
- Contribution to journal › Article
-
Mark
Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics
(
- Contribution to journal › Article
-
Mark
Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B
(
- Contribution to journal › Article
-
Mark
Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy : The Malmö experience
(
- Contribution to journal › Article
-
Mark
The association between health utility and joint status among people with severe haemophilia A : findings from the KAPPA register
(
- Contribution to journal › Article
-
Mark
Comparative burden of arthropathy in mild haemophilia : a register-based study in Sweden
(
- Contribution to journal › Article
-
Mark
Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients : Results of the INSIGHT case-control study
(
- Contribution to journal › Article
- 2016
-
Mark
Current view and outcome of ITI therapy : A change over time?
(
- Contribution to journal › Article
-
Mark
Partnering to change the world for people with haemophilia : 6th Haemophilia Global Summit, Prague, Czech Republic, 24–26th September 2015
(
- Contribution to journal › Published meeting abstract
-
Mark
Malignancies in Swedish persons with haemophilia : a longitudinal registry study
(
- Contribution to journal › Article
- 2015
-
Mark
Strategies for reducing inhibitor formation in severe haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Genetic risk factors for inhibitors in haemophilia A
(
- Contribution to journal › Scientific review
-
Mark
Non-genetic risk factors and their influence on the management of patients in the clinic
(
- Contribution to journal › Scientific review
-
Mark
FVIII inhibitors: pathogenesis and avoidance.
(
- Contribution to journal › Scientific review
- 2014
-
Mark
A longitudinal study of family structure in Swedish persons with haemophilia.
(
- Contribution to journal › Article
-
Mark
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
(
- Contribution to journal › Letter
-
Mark
Managing Haemophilia for Life: 4th Haemophilia Global Summit
(
- Contribution to journal › Scientific review
-
Mark
Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B - a systematic literature review
(
- Contribution to journal › Scientific review
-
Mark
The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity
(
- Contribution to journal › Article
-
Mark
Clinically relevant non-neutralizing anti-FVIII antibodies in a hemophiliac
(
- Contribution to journal › Letter
- 2013
-
Mark
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
(
- Contribution to journal › Article
-
Mark
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
(
- Contribution to journal › Article
-
Mark
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy.
(
- Contribution to journal › Article
-
Mark
Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden.
(
- Contribution to journal › Article
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Article
- 2012
-
Mark
Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
(
- Contribution to journal › Letter
-
Mark
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
(
- Contribution to journal › Scientific review
-
Mark
The international factor IX treatment network survey.
(
- Contribution to journal › Letter
-
Mark
Prevention and prediction of inhibitor risk.
(
- Contribution to journal › Article
-
Mark
Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
2012) In Haemophilia(
- Contribution to journal › Article
-
Mark
Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
(
- Contribution to journal › Article
-
Mark
Malignant disease in the haemophilic population: moving towards a management consensus?
(
- Contribution to journal › Article
-
Mark
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
(
- Contribution to journal › Article
-
Mark
The Arosenius Fund.
(
- Contribution to journal › Article
-
Mark
Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
(
- Contribution to journal › Article
- 2011
-
Mark
Immune tolerance induction in patients with hemophilia A
(
- Contribution to journal › Article
-
Mark
Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions
(
- Contribution to journal › Article
-
Mark
The international factor IX treatment network survey
(
- Contribution to journal › Published meeting abstract
-
Mark
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
(
- Contribution to journal › Article
-
Mark
Bone density and health-related quality of life in adult patients with severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Recommendations for assessment, monitoring and follow-up of patients with haemophilia.
2011) In Haemophilia(
- Contribution to journal › Article
-
Mark
Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
Ovanliga ärftliga former av blödarsjuka. Blödningssymtom, familjehistoria och laboratorieanalyser ger diagnosen.
(
- Contribution to journal › Article
- 2010
-
Mark
Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate haemophilia A: first results from the INSIGHT study
(
- Contribution to journal › Published meeting abstract
-
Mark
Clinical issues in inhibitors
(
- Contribution to journal › Scientific review
-
Mark
Differential response to bypassing agents
(
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Influence of the pre-analytical specimen storage conditions on thrombin generation assay
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.45-45(
- Contribution to journal › Published meeting abstract
-
Mark
F8 haplotype and recombinant product use in the Hemophilia Inhibitor Genetics Study (HIGS)
(
- Contribution to journal › Published meeting abstract
-
Mark
Assessment of health-related quality of life in patients with severe haemophilia with reduced bone density
(
- Contribution to journal › Published meeting abstract
-
Mark
Mild haemophilia in Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
(
- Contribution to journal › Article
-
Mark
Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
(
- Contribution to journal › Article
-
Mark
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
(
- Contribution to journal › Article
-
Mark
Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
(
- Contribution to journal › Article
-
Mark
Inhibitor development: patient-determined risk factors.
(
- Contribution to journal › Article
-
Mark
Von Willebrands sjukdom--från biokemi till klinisk praxis.
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Arandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
(
- Contribution to journal › Article
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
(
- Contribution to journal › Article
-
Mark
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy
2009) 10th International Symposium on Myelodysplastic Syndromes In Leukemia Research 33(Suppl 1). p.49-50(
- Contribution to journal › Published meeting abstract
-
Mark
Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Published meeting abstract
-
Mark
Characterization of a Novel Aberrant Splice Site, 79bp Downstream of Exon 5 in the Human Factor 7 Gene Detected in Patients with Severe Congenital Factor VII Deficiency.
(
- Contribution to journal › Published meeting abstract
-
Mark
Cumulative incidence of inhibitors: it is influenced by type of replacement therapy in previously treated boys with severe haemophilia A. No
(
- Contribution to journal › Published meeting abstract
-
Mark
European curriculum for thrombosis and haemostasis.
(
- Contribution to journal › Article
- 2008
-
Mark
Value added: increasing the power to assess treatment outcome in joint haemorrhages
(
- Contribution to journal › Article
-
Mark
New risk factors for inhibitor development
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.43-43(
- Contribution to journal › Published meeting abstract
-
Mark
The importance of maintaining FVIII through levels above 1% during prophylactic treatment of hemophilia A: using license study databases to answer key medical questions
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.58-58(
- Contribution to journal › Published meeting abstract
-
Mark
Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy
(
- Contribution to journal › Published meeting abstract
-
Mark
Thrombin generation assay: a useful tool in the management of haemophilia A patients?
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.26-26(
- Contribution to journal › Published meeting abstract
-
Mark
European principles of haemophilia care
(
- Contribution to journal › Article
-
Mark
From theory to practice: Applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors
(
- Contribution to journal › Scientific review
-
Mark
Variability of clinical manifestations of factor VII-deficiency in subjects homozygous or heterozygous for the F7 gene mutation A294V
(
- Contribution to journal › Letter
-
Mark
Inhibitor development.
(
- Contribution to journal › Article
-
Mark
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
(
- Contribution to journal › Article
- 2007
-
Mark
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
The APC-PCI complex concentration predicts outcome of aortic surgery.
(
- Contribution to journal › Article
-
Mark
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
(
- Contribution to journal › Article
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor.
(
- Contribution to journal › Article
-
Mark
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
- 2006
-
Mark
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
(
- Contribution to journal › Article
-
Mark
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Overview of inhibitors.
(
- Contribution to journal › Article
-
Mark
Overview of inhibitors
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Inhibitor development in hemophiliacs: The roles of genetic versus environmental factors
(
- Contribution to journal › Article
- 2005
-
Mark
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival.
(
- Contribution to journal › Article
-
Mark
Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods.
(
- Contribution to journal › Letter
-
Mark
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.
(
- Contribution to journal › Article
- 2003
-
Mark
Monitoring the bioavailability of FEIBA with a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
When to start and when to stop primary prophylaxis in patients with severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
(
- Contribution to journal › Letter
-
Mark
Thrombosis in inherited factor VII deficiency.
(
- Contribution to journal › Article
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
(
- Contribution to journal › Article
-
Mark
Treatment of the bleeding inhibitor patient
(
- Contribution to journal › Article
- 2002
-
Mark
Unresolved issues in prophylaxis
(
- Contribution to journal › Article
-
Mark
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
(
- Contribution to journal › Article
-
Mark
The prognostic value of global haemostatic tests in the intensive care unit setting.
(
- Contribution to journal › Article
-
Mark
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
(
- Contribution to journal › Article
- 2001
-
Mark
Anti- and procoagulant activities in factor VII-deficient subjects
(
- Contribution to journal › Article
-
Mark
The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
(
- Contribution to journal › Article
-
Mark
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis
(
- Contribution to journal › Article
-
Mark
Symposium in memory of Professor Inga Marie Nilsson
(
- Contribution to journal › Published meeting abstract
- 2000
-
Mark
Correlation between different intensities of anti-vitamin K treatment and coagulation parameters
(
- Contribution to journal › Article
-
Mark
The Malmo model for immune tolerance induction: impact of previous treatment on outcome
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction and the treatment of hemophilia. Malmo protocol update
(
- Contribution to journal › Article
- 1999
-
Mark
The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarin-treated patients from control subjects
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
(
- Contribution to journal › Article
-
Mark
Malmo International Brother Study (MIBS): an international survey of brother pairs with haemophilia
(
- Contribution to journal › Article
- 1998
-
Mark
Major surgery seems not to influence HIV disease progression in haemophilia patients
(
- Contribution to journal › Article
-
Mark
The Malmo-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts
(
- Contribution to journal › Scientific review
-
Mark
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation
(
- Contribution to journal › Article
-
Mark
Calcium binding to the first EGF-like module of human factor IX in a recombinant fragment containing residues 1-85. Mutations V46E and Q50E each manifest a negligible increase in calcium affinity
(
- Contribution to journal › Article
-
Mark
Blödarsjuka med HIV. Långsammare infektionsförlopp hos yngre och vid större förbrukning av faktorkoncentrat
(
- Contribution to journal › Article
- 1997
-
Mark
No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products
(
- Contribution to journal › Article
- 1996
-
Mark
Antitrombin III-koncentrat söker sin roll i terapin. Var försiktig och invänta studieresultat!
(
- Contribution to journal › Article
- 1994
-
Mark
The gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IXa beta. Effects on the serine protease module and factor X activation
(
- Contribution to journal › Article
-
Mark
Baculovirus-mediated expression of the epidermal growth factor-like modules of human factor IX fused to the factor XIIIa transamidation site in fibronectin. Evidence for a direct interaction between the NH2-terminal epidermal growth factor-like module of factor IXa beta and factor X
(
- Contribution to journal › Article
- 1993
-
Mark
Isolation of intact modules from noncatalytic parts of vitamin K-dependent coagulation factors IX and X and protein C
(
- Contribution to journal › Article
- 1992
-
Mark
Effects of gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IX on factor X activation. Studies using proteolytic fragments of bovine factor IX
(
- Contribution to journal › Article
- 1991
-
Mark
Structural requirements for Ca2+ binding to the gamma-carboxyglutamic acid and epidermal growth factor-like regions of factor IX. Studies using intact domains isolated from controlled proteolytic digests of bovine factor IX
(
- Contribution to journal › Article
-
Mark
The epidermal growth factor-like domains of factor IX. Effect on blood clotting and endothelial cell binding of a fragment containing the epidermal growth factor-like domains linked to the gamma-carboxyglutamic acid region
(
- Contribution to journal › Article
-
Mark
Epidermal growth factor-like domains in the vitamin K-dependent clotting factors. Some structure-function relationships
(
- Contribution to journal › Article